Search clinical trials for: Bruton's tyrosine kinase inhibitor

Total 68325 results

AB Science

Recruiting

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Amyotrophic Lateral Sclerosis

France, Spain, United States, Sweden, Denmark, Portugal, Italy, Israel, Germany, Norway, Poland, Russian Federation, Slovenia, Ukraine, Greece, Belgium, Serbia
M.D. Anderson Cancer Center

Recruiting

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

Chronic Lymphocytic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI); EsPhALL Network/ BFM Study Group

Recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States, Canada, Puerto Rico, Australia, Finland, New Zealand, Saudi Arabia, Germany, Austria, Belgium, Chile, Czechia, France, Italy, Netherlands, Sweden, Switzerland, Hong Kong, Israel
Brian Jonas
National Cancer Institute (NCI); Pharmacyclics LLC.

Recruiting

Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia

Philadelphia Chromosome Positive | Adult B Acute Lymphoblastic Leukemia

United States
Sun Yat-sen University

Recruiting

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

China
Tata Memorial Hospital

Recruiting

TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer (TACE-SBRT)

Carcinoma, Hepatocellular

India
Versailles Hospital

Recruiting

Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW)

Leukemia, Myeloid, Chronic-Phase

France
Giselle Sholler
Beat NB Cancer Foundation; K C Pharmaceuticals Inc.; Team Parker for Life; Dell...

Recruiting

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN)

Neuroblastoma

United States, Canada
Canadian Cancer Trials Group
Roche Pharma AG; Janssen, LP; Karyopharm Therapeutics Inc

Recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Lymphoma

Canada
National Cancer Institute (NCI)

Recruiting

Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors

Solid Tumors

United States
National Cancer Institute (NCI)

Recruiting

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Primary Central Nervous System Lymphoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...

United States, Guam, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Guam, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
M.D. Anderson Cancer Center
Astellas Pharma Inc; The Kadoorie Charitable Foundations

Recruiting

Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection

Head and Neck Cancer

United States
University of Pisa

Recruiting

TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study (TIKlet)

Chronic Myeloid Leukemia

Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors (CML1012)

Pregnancy | Chronic Myeloid Leukemia

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
QuantumLeap Healthcare Collaborative

Recruiting

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)

Breast Cancer | Breast Neoplasms | Breast Tumors | HER2-positive Breast Cancer | Angiosarcoma | Locally Advanced Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | Hormone Receptor Positive Tumor | Hormone Receptor Negative Tumor | Early-stage Breast Cancer

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

Hypereosinophilic Syndrome | Eosinophilic Myeloid Neoplasm

United States
Theseus Pharmaceuticals

Terminated

A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Diseases | Neoplasms | Neoplasms, Connective and Soft Tissue | Neoplasms by Histologic Type | Gastrointestinal Neoplasms | Neoplasms, Connective Tissue | Digestive System Neoplasm | Digestive System Disease | Gastrointestinal Stromal Tumors (GIST)

United States
National Cancer Institute (NCI)

Active, not recruiting

Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

Central Nervous System Lymphoma | Secondary Central Nervous System Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Heart, Lung, and Blood Institute (NHLBI)

Enrolling by invitation

Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

Immune Mediated Anemia | Immune Mediated Thrombocytopenia | Chronic GVHD

United States
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS) | Aggressive B-cell Lymphoma With Secondary Involvement of the CNS

United States
Merck Sharp & Dohme LLC

Terminated

A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)

Breast Cancer | Advanced Solid Tumors
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
M.D. Anderson Cancer Center

Completed

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
Prof. Wolfgang Janni

Completed

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs (DETECT III)

HER2-negative Metastatic Breast Cancer | HER2-positive Circulating Tumor Cells

Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Non-small Cell Lung Cancer

Korea, Republic of, Taiwan, United States, China, Hong Kong, France, Russian Federation, Netherlands, Japan, Spain, Italy, Belgium, Vietnam, Malaysia, Thailand, Germany, Singapore
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma | Breast Inflammatory Carcinoma

United States
Hoffmann-La Roche

Completed

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Acute Myeloid Leukemia

Australia, Italy, Canada, United Kingdom, United States, Denmark, Spain, Taiwan, Germany, France
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia Variant | Recurrent Hairy Cell Leukemia Variant

United States
Trans Tasman Radiation Oncology Group

Completed

A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases (OUTRUN)

Metastatic Non Small Cell Lung Cancer

Singapore, Australia
M.D. Anderson Cancer Center

Suspended

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Mantle Cell Lymphoma

United States
Celgene
AbbVie

Terminated

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States, Canada, France, United Kingdom, Belgium
Akeso
Akeso Tiancheng, Inc

Completed

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Lymphoma, Non-Hodgkin | B-cell Lymphoma | Multiple Myeloma | Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, B-cell Marginal Zone

United States, France, Poland, Italy
Novartis Pharmaceuticals

Active, not recruiting

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

GIST and CML

China, Finland, Turkey, Singapore, France, Switzerland, Thailand, Romania, Hong Kong, United Kingdom, United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)

Chronic Lymphocytic Leukemia

United States, Spain, Canada, Italy, Taiwan, Russian Federation, Turkey, Germany, Korea, Republic of, Brazil, Hungary, Poland, China, Sweden, Bulgaria, Israel, United Kingdom, Australia, Saudi Arabia, Austria, France, Czechia, South... and more
Acerta Pharma BV

Active, not recruiting

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL (ElevateTN)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, Belgium, Brazil, Poland, United Kingdom, Canada, Germany, Australia, Israel, Hungary, France, New Zealand, Chile, Lithuania, Sweden, Colombia
University of Chicago
National Cancer Institute (NCI)

Terminated

Afatinib in Advanced Refractory Urothelial Cancer

Recurrent Bladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Ureter Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Stage III Urethral Cancer | Stage IV Urethral Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Autoimmune Hemolytic Anemia | Warm Antibody Autoimmune Hemolytic Anemia | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
National Cancer Institute (NCI)

Completed

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Solid Tumors

United States
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Adult T Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Adult L1 Acute Lymphoblastic Leukemia | Adult L2 Acute Lymphoblastic...

United States
AstraZeneca

Active, not recruiting

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Untreated Chronic Lymphocytic Leukemia

Thailand, Vietnam, Philippines, China, Taiwan
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

Leukemia, Lymphocytic, Chronic, B-Cell

Canada, Belgium, Netherlands, Spain, Israel, United States, Czechia, Denmark, United Kingdom, France, Russian Federation, Turkey, Poland, Sweden

Search clinical trials for: Bruton's tyrosine kinase inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations